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Abstract 
Approximately two-third of the compounds in the pharmaceutical industry were developed through 
combinatorial chemistry and high throughput screening of particulate solids. Poor solubility and 
bioavailability of these pharmaceuticals are challenging attributes confronted by a formulator during 
product development. Hence, substantial efforts have been directed into the research on particle 
generation techniques. Although the conventional methods, such as crushing or milling and crystallization 
or precipitation, are still used; supercritical fluid technology introduced in the mid-1980s presents a new 
method of particle generation. Supercritical fluid processes not only produce micro- and nanoparticles 
with a narrow size distribution, they are also employed for the microencapsulation, cocrystallization, and 
surface coating with polymer. Recognized as a green technology, it has emerged as successful variants 
chiefly as Rapid Expansion of supercritical solutions (RESS), Supercritical anti-solvent (SAS) and Particles 
from Gas Saturated Solution (PGSS) depending upon type of solvent, solute, antisolvent and nebulization 
techniques. Being economical and eco-friendly, supercritical fluid technolgy has garnered considerable 
interest both in academia and industry for modification of physicochemical properties such as particle size, 
shape, density and ultimately solubility. The current manuscript is a comprehensive update on different 
supercritical fluid processes used for particle generation with the purpose of solubility enhancement of 
drugs and hence bioavailability. 
©2020 by the authors. This article is an open-access article distributed under the terms and conditions of the Creative Commons 
Attribution license (http://creativecommons.org/licenses/by/4.0/). 
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Introduction 
In the last decade, supercritical fluid (SCF) processes have been extensively utilized for pursuing 
chemical reactions, extraction, crystallization, precipitation, purification, and development of micro- and 
nanoparticles. Considerable research efforts are being made to modify solubility and improvement of 
bioavailability of poorly soluble drugs through SCF. As a well known fact the bioavailability of drugs 
depends on the absorption through gastrointestinal tract that is in turn governed by their solubility and 
dissolution. Thus the particle size is of utmost importance. Conventional methods such as crushing, milling, 
crystallization and precipitation are commonly utilized for particle development in the pharmaceutical 
industry. Each of these methods has their own set of limitations. SCF technology presents an innovative 
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approach for particle formation that evades most of the downsides related to the traditional methods [1]. 
Hence, the technology has firmly positioned itself in the pharmaceutical arena. SCF finds a vital application 
in the development of dry powder inhalers (mean particle size of 2 to 5 µm) that accurately deliver precise 
dose to the lungs. Furthermore, SCF technology can be explored for the development of sustained and 
controlled release systems via microencapsulation [2,3], coating and formation of composite particles [4]. 
This technology is eco-friendly, green process that generates less waste during operation and produces fine 
product at minimum cost. 
The accuracy presented by SCF processes permits micronization of drug particles, often to submicron 
stage. The SCF processes can generate nanosuspensions of particles to the tune of 5-2,000 nm [5]. The 
technology acts as a re‐precipitation aid for rapid and uniform nucleation of the solute in all its variants of 
fine particle formation. The performance efficiency of this technology is based on proper solvent selection 
and by adjusting critical parameters (temperature and pressure) during operations (Fig. 1).  
As documented in the literature, Rapid 
Expansion of Supercritical Solutions (RESS), 
Supercritical Anti Solvent (SAS) and Particles 
from Gas Saturated Solutions (PGSS) are the 
frequently employed methods not only for 
the fabrication of monodisperse fine 
powders, but also to control crystal 
polymorphism. It is also established that 
RESS can be used for CO2 soluble molecules, 
while SAS can process non-soluble 
molecules. However, the selection is not so 
simple and a good knowledge of operating 
conditions and phase equilibrium 
thermodynamics is required.  
SCF methods not only produce micro- and nanoparticles of uniform size distribution, but are extensively 
applied for microencapsulation and polymeric surface coating on drug crystals, cocrystallization with 
excipients and development of soluble complexes with cyclodextrin. Nijlen et al. [6] demonstrated 
significant reduction in particle size of artemisinin and improved dissolution rate when processed with SCF 
technology. Table 1 lists various SCF techniques that can be used for solubility enhancement based on 
particle generation. 
SCF processes find vital applications in almost all drug delivery routes, such as oral, intravenous, 
ophthalmic, pulmonary, transdermal, and implants. Revercheon et al. [7] emphasized the construction of 
various nanostructures i.e. nanofibers, nanotubes, nanowires, nanoparticles and other nano-constructions 
using supercritical fluid-based techniques. Byrappa et al. [8] explored the adaptive properties of SCF for the 
synthesis of advanced nanomaterials including carbon nanotubes, fullerenes, magnetic particles, quantum 
dots, phosphors, nanocomposites (peptide/hydroxyapatite), and gold nanoshells for drug delivery and 
other biomedical applications such as imaging, sensing, and cancer theranostics. The review elaborates the 
applications of Rapid Expansion of Supercritical Solutions (RESS), Supercritical Anti Solvent (SAS) and 
Particles from Gas Saturated Solutions (PGSS) for the generation of micro- and nano sized drug particles 
and composite particles. The write up also entails other SCF technologies that have been used for solubility 
enhancement of poorly water soluble drugs. 
 
Figure 1. Scheme of the SCF technology process 
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Solvent  Rapid expansion of supercritical solution (RESS) 
Rapid expansion of supercritical solution into a liquid solvent ( RESOLV) 
Rapid expansion of supercritical solution into an aqueous solution (RESS-AS) 
Rapid expansion of supercritical solution with a non-solvent (RESS-N) 
Anti-solvent Gas anti-solvent (GAS) 
Supercritical anti-solvent (SAS) 
Aerosol Solvent Extraction System (ASES) 
Particles by Compressed Anti-solvent (PCA) 
Solution Enhanced Dispersion by Supercritical Fluids (SEDS) 
Solute  Particles from Gas-Saturated Solutions (PGSS) 
Depressurization of an Expanded Liquid Organic Solution (DELOS) 
RESS for particle generation  
RESS is composed of two steps, first to dissolve the solid compound in a supercritical fluid, and the 
second step results in the formation of particles by the virtue of supersaturation. The supercritical fluid 
(CO2) is allowed to pump at required pressure and temperature to the solid substance contained in the 
extraction chamber. The supercritical fluid expands adiabatically in the vessel, triggering a downfall of 
temperature and pressure, leading to the formation of fine particles [9,10]. Hasty expansion of the 
supercritical solution causes reduction in the density and hence particle precipitation with minimum 
residual solvent occurs (Fig. 2). 
 
Figure 2. RESS process depicted diagrammatically for solubility enhancement of a hypothetical drug 
Charoenchaitrakool et al. [11] aimed at micronization of racemic ibuprofen and examined the 
dissolution rate of the micronized product in a buffered solution. The solubility data at various 
temperatures was modeled using Peng-Robinson equations of state with Vander Waals mixing rules. The 
solubility of (S)-ibuprofen exhibited solubility in CO2 similar to (R)-form. The aggregated particles were 
easily dispersed by ultrasonication in water. The degree of crystallinity was slightly decreased and the 
intrinsic dissolution rate was higher than the original form. Likewise the amorphous nanoparticles of 
cefuroxime axetil were produced directly by RESS technology, without any additive. The nanoparticles 
obtained were between 158 and 513 nm. More than 90 % of the nanoparticles dissolved in 3 min and 
complete dissolution occurred within 20 min, while the commercial drug achieved only about 50 % 
dissolution in 60 min [12]. 
Bioavailability of the pharmaceutical substances is very important for their activity. In case of necessity, 
bioavailability can be improved by reducing the particle size of the drugs. Hezave and Esmaeilzadeh [13] 
aimed to manufacture fine particles of diclofenac and optimize the RESS conditions for generating uniform 
particles. Micronization resulted in the average particle size between 10.92 and 1.33 μm. The morphology 
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of the processed particles changed to quasi-spherical while the virgin particles of diclofenac were irregular. 
Similarly, the reduction in particle size of digitoxin was achieved by Atila et al., [14] and response surface 
method was used to optimize the process parameters. The particle size of digitoxin was decreased from 
0.2-8 µm to 68-458 nm by RESS technique and 97 % of the particles were below 200 nm depending on the 
different experimental conditions.  
The solubility of the drug substance in supercritical CO2 has a major effect on the average diameter of 
the particles prepared by RESS process. This was proved by Kim et al. when they used RESS for the 
preparation of ultra-fine drug particles using supercritical CO2, with no organic solvent. Three drug 
substances (lidocaine, griseofulvin, benzoic acid) with different solubility in supercritical CO2 were used, 
and orifice disks and capillary tubes were adapted as an expansion device. The solubilities of drug 
substances in supercritical CO2 and the effects of various operating parameters on the characteristics of 
the particles prepared by RESS process were experimentally investigated. The solubility of the drug 
substance in supercritical CO2 had a major effect on the average diameter of the particle prepared by RESS 
process, and the particle diameter decreased with the solubility for all the drugs and operating conditions 
[15]. In another report, the particle size of raloxifene was reduced from 45 μm to 19 nm by RESS process, 
the smallest of which was 18.93 nm. In addition, dissolution rate study indicated that a 7-fold increase in 
dissolution rate could be obtained by particle size reduction of raloxifene using RESS. Response Surface 
Methodology was used for the optimization of the results and it was demonstrated that the smallest 
particle size could be achieved at a temperature of 50 °C, pressure of 17.7 MPa and a spray distance of 
10 cm [16]. 
In addition to particle size reduction, RESS can also be used to achieve microencapsulation and surface 
coating of an active substance particle with a polymer or co-crystallization with excipients or host 
molecules like cyclodextrins. Kim et al. [17] used RESS process to produce polymeric microparticles loaded 
with naproxen for drug delivery applications. Poly (L‐lactic acid) (L‐PLA), naproxen, and a mixture of 
naproxen and L‐PLA were dissolved in supercritical CO2 and precipitated by the RESS process. Composite 
particles appeared as a naproxen core encapsulated in a polymer coating. Mishima et al. [18] reported a 
new method — Rapid Expansion from Supercritical Solution with a non-solvent (RESS-N) for forming 
polymer microparticles containing proteins such as lysozyme and lipase. A suspension of protein in CO2 was 
made that contained a cosolvent and a dissolved polymer amongst poly (ethylene glycols), poly (methyl 
methacrylate), poly (L-lactic acid), poly (DL-lactide-co-glycolide) and PEG–poly(propylene glycol) (PPG)–PEG 
triblock copolymer. The solubilities of these polymers in CO2 increased significantly with low-molecular-
weight alcohols as cosolvents. The wide applications of RESS namely micronization and nanonization of 
APIs and generation of composite particles is further summarized in Table 2. 
SAS process for particle generation 
The SAS process is a highly useful for the micronization and nanonization of synthetic drugs and natural 
compounds. This method refers to the precipitation of compounds in a provided supercritical fluid. The 
selected supercritical fluid should be essentially miscible with solvent whereas the solute should be 
insoluble in supercritical anti-solvents. To process SAS, selection of solvent depends upon two types of 
requisites, first is good miscibility with CO2 i.e. ethanol, acetone, toluene; and second is the solubility of 
solute to be precipitated. Indeed, the solvent must usually belong to class 3 (non-toxic) of the 
pharmaceutical guidelines. In any case, the amount of residual solvent in the crystallized powder must not 
exceed 5000 ppm. 
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Table 2 A cross section of micronization and nanonization of some drugs using RESS technology 
API Objective Research highlight Ref 
Coumarin  
 
Coumarin nanoparticles were 
prepared and the effect of 
temperature, pressure, spray 
distance and nozzle diameter on 
particle size and solubility was 
assessed. 
A considerable decline in particle size was observed from 
40.35 μm to 21.37 nm thereby affecting solubility. 
Quadrupolar cubic plus association theory and perturbed-
chain polar statistical associating fluid theory were applied 





RESS was used to reduce particle 
size. The solubility study of poorly 
soluble drugs was performed 
employing five cubic equation of 
state (EoS) with two mixing rules. 
Based on the calculated solubilities, two of the most 
accurate equations of state are PR-vdW and PR-KM with 





The solubility of ipriflavone was 
enhanced through the RESS 
process using supercritical CO2. 
Results outlined improved solubility of ipriflavone in 
supercritical CO2. Additionally, the particle size was 





RESS with solid cosolvent (RESS-
SC) was employed to precipitate 
nanoparticles of letrozole 
Obtained findings suggested enhanced solubility of 
letrozole (7.1 times) in the ternary phase with solid co-
solvent application in RESS process. The average particle 




Effect of parameters i.e. pressure, 
temperature, spraying distance 
and nozzle diameter was studied 
on the nanoparticles morphology. 
Significant reduction in the particle size (micrometer to 
nanometer) was observed for the nanoparticles developed 
through RESS-SC method. The dissolution rate of 
aprepitant was increased by 8.2 times, suggesting 
improved solubility of the drug.  
[23] 
TBTPP (5, 10, 
15,20-tetrakis (3, 
5-bis- tri fluoro 
methyl phenyl 
porphyrin  
RESS process was investigated 
applying numerical modeling for 
particle formation of TBTPP. 
Peng-Robinson EoS with Kwak-Mansoori mixing rules were 
applied after the optimization of pressure and 
temperature. The improved solubility was measured by 
numerical modeling and the results were compared with 
experimental data.  
[24] 
Progesterone  Fine progesterone particles were 
produced and the solubility was 
analyzed by varying temperature 
and pressure and compared with 
a well known model. 
The solubility studies were correlated with empirical 
density-based models and the Peng-Robinson equation of 









A novel fluidized-bed coating 
process using RESS was described 
for the coating of fine particles.  
Microspheroidal catalyst particles (average particle size 56 
μm) were used as the core particles. Supercritical CO2 
solution of paraffin was expanded through the nozzle into 
the bed that was fluidized by air. The coating mass and 
coating rates were measured by a sampling method. A 
stable coating of fine particles was achieved without the 




RESS was used as a means of 
simultaneous micronization and 
cocrystallization of drugs with 
poor aqueous solubility. 
1:1 cocrystals of ibuprofen and nicotinamide with high 
purity were produced. The specific surface area of RESS 
cocrystals was increased by almost tenfold in comparison 
to cocrystals produced by slow solvent evaporation and 
the mean dissolution time of ibuprofen from RESS 
cocrystals was decreased. For drugs with dissolution- 
limited bioavailability, RESS cocrystallization may be a 
superior approach in comparison to established 
cocrystallization techniques. 
[27] 
Many pharmaceuticals have been processed using SAS and derived processes (SEDS, PCA, ASES). A very 
broad range of molecules can be used namely antibiotics, proteins, biopolymers, paracetamol, salbutamol, 
naproxen, ascorbic acid etc [28]. Kordikowski et al. [29] worked with sulfathiazole, a compound that 
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exhibits five different polymorphs. Using a semi-continuous SAS process with methanol and CO2, the 
researchers were able to produce pure polymorph by controlling the flow rate of methanol and the 
temperature. Three pure polymorphs I, III and IV could be obtained by choosing the right temperature 
while the flow rate, and the ratio of methanol: CO2 had less influence on the polymorphs. The method is 
widely studied today because of its potential industrial applications.  
A semi-continuous SAS precipitation has been used to produce rifampicin micro- and nanoparticles with 
controlled particle size and particle size distribution; using different liquid solvents. The best micronization 
results were obtained using dimethyl sulfoxide at 400 °C. The nanoparticles with mean diameter ranging 
from 0.4 to 1 µm were obtained at a pressure of ≥ 120 bars, while microparticles with mean diameter 
ranging from 2.5 to 5 µm were obtained at pressures between 90 and 110 bars. The morphology of 
rifampicin precipitates was different too. Nanoparticles connected in small aggregates were obtained at 
pressures higher than 120 bars, whereas, spherical single microparticles were obtained at lower operating 
pressures [30].  
In a research work, a swirl mixer was employed to produce the micronized curcumin with polyvinyl 
pyrrolidone (PVP) by the SAS process to improve the bioavailability of curcumin. The effects of operating 
parameters such as curcumin: PVP ratio, feed concentration, temperature, pressure, and CO2 flow rate 
were investigated. The result showed that the optimal condition for the production of curcumin-PVP 
particles were at curcumin:PVP ratio of 1:30, feed concentration of 5 mg/mL, temperature of 40 °C, 
pressure of 15 MPa, and CO2 flow rate of 15 mL/min. Curcumin-PVP particles (< 150 nm) were completely 
soluble in aqueous solution to form a clear yellow solution unlike poorly soluble raw curcumin. The 
solubility of curcumin-PVP particles was 2.34 µg/mL whereas that of raw curcumin was 0.006 µg/mL after 
12 h. The reason attributable was that the water-soluble polymer (PVP) can modify the surface properties 
of the particle and thus enhance the solubility of curcumin in aqueous solution [31].  
SAS process was used for telmisartan (BCS class II drug) in a variety of ways including micronization, 
amorphization and solid dispersion. Solid dispersions were prepared using HPMC and PVP at 1:0.5, 1:1, and 
1:2 weight ratios of drug to polymer, and pure telmisartan was also treated using the SAS process. After 
the SAS process, all samples were converted to the amorphous form and were hundreds nm in size. 
Solubility and dissolution rate were increased compared to the raw material. Though the drug’s solubility 
increased with increase in the amount of polymer used; the dissolution rate decreased with increasing 
polymer concentration. Processed pure telmisartan showed higher drug release than its original form, even 
though it had lower solubility compared to other solid dispersions. The authors concluded that that after 
controlling the formulation of solid dispersion, the SAS process could be a promising approach for 
improving the solubility and dissolution rate of telmisartan [32]. 
The SAS process was used to modify the solid state characteristics of fluconazole by preparing its 
polymorphs by varying the temperature, pressure and solvents. Fluconazole anhydrate form I was 
obtained at low temperature (40 °C) and anhydrate form II was obtained at high temperature (80 °C). Not 
much difference was found in solubility of the polymorphs [33]. The same research group improved 
dissolution rate of poorly water-soluble drug, cilostazol, using SAS process. In particular, the mean particle 
size and distribution were markedly influenced by drug solution concentration during SAS process. 
Moreover, the drug did not change its crystal form and the operating parameters probably controlled the 
'crystal texture'. The micronized particles exhibited a 6.5 fold increase in dissolution rate compared to the 
unprocessed cilostazol [34]. Likewise, amorphous SAS treated nanoparticles of atorvastatin calcium 
showed increased bioavailability of atorvastatin owing to their nano-dimensional size that offered high 
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solubility and increased dissolution rate. The oral absorption of amorphous atorvastatin calcium 
nanoparticles in rats was obviously higher when compared with the crystalline atorvastatin calcium after a 
single dose of 25 mg/kg. The AUC0-12h of the amorphous atorvastatin calcium nanoparticles (179 nm) was 
2.1 times that of unprocessed drug. Thus, the SAS process for generation of amorphous atorvastatin 
calcium nanoparticles is a promising method for enhancing their bioavailability [35].  
The SAS process can also be utilized to establish co-precipitation of two different compounds and to 
form beta cyclodextrin complexes of poorly soluble drugs. The inclusion complex of apigenin-
hydroxypropyl -beta-cyclodextrin was prepared through a SAS process and its bioavailability was evaluated. 
The inclusion complex exhibited improved wettability and the dissolution of apigenin inclusion complex 
was significantly enhanced. The inclusion complex demonstrated an enhanced oral bioavailability of 
approximately 6 fold when compared to pure apigenin, in rats [36]. Table 3 summarizes few additional 
applications of SAS process in improving solubility, dissolution or drug release of certain poorly soluble 
pharmaceuticals. 
Table 3. A compilation of reports on solubility enhancement of poorly soluble drugs affected by SAS technology 
API Objective Outcome Ref 
Tolfenamic acid SAS parameters were evaluated for 
solid state property modification 
and improvement of dissolution 
profile of tolfenemic acid. 
 SAS technology was efficient in modifying the solid-
state. It produced microparticles with improved 
dissolution behavior. 
[37] 
N-acetyl-cysteine  The study aimed to micronize N-
acetylcysteine by the anti-solvent 
SEDS technique. 
Micronized N-acetylcysteine presented prominent 
biological activity (100 times) depicted by lower 
minimum inhibitory concentration compared to 
non-micronized N-acetylcysteine  
[38] 
Curcumin  Curcumin based dye extract was 
developed employing SAS. 
Eudragit® L100, Pluronic® 127 and 
tween 20 were added to improve 
the aqueous solubility and stability. 
Formulation of a soluble curcumin was carried out 
for food application. Highest aqueous stability and 
solubility was observed at pH 4. The mean diameter 
and zeta potential of the amorphous curcumin 
particles was 5667.4 nm and 11.21 mV respectively.  
[39] 
Warfarin  To determine solubility of warfarin 
in supercritical CO2 using SAS 
Regular crystals of warfarin with a mean particle 
size of 6.6 μm were produced 
[40] 
Irbesartan To improve the dissolution of 
irbesartan through solid dispersions 
using SAS concept. 
The crystalline state of the drug was transformed 
into the amorphous state. The dissolution was 
enhanced after formation of irbesartan solid 
dispersions  
[41] 
Azithromycin Solid dispersions of azithromycin 
were developed utilizing variable 
amounts of PEG 6000, sorbitol, SLS 
and Poloxamer 188,  
The amorphous solid dispersions of azithromycin 
demonstrated enhanced solubility with PEG 6000 
and SLS. 
[42] 
The SAS technology offers reasonable morphology, high drug loading and improved bioavailability but 
occasionally leads to particle aggregation that can be resolved by use of ultrasonic processor [43]. Among 
the various SAS based micronization techniques reported, the SEDS (solution enhanced dispersion by 
supercritical fluids) is an efficient process for the development of uniform sized nanoparticles [44]. York 
and Hanna developed modified SAS or SEDS process in 1996. This revised technique curtails the drawbacks 
and limitations of SAS and produces completely dried, uniform, narrow sized particles with low residual 
organic solvent [45]. In this modified SAS system, initially the drug and excipients are allowed to dissolve in 
an appropriate organic solvent followed by rigorous agitation. Thereafter, the blended components come 
in contact with the supercritical fluid. Especially designed coaxial nozzle in SEDS process efficiently sprays 
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the components at high pressure that results in micronized uniform particles (Fig. 3). 
SEDS has been employed to enhance dissolution of baicalein via micronization of baicalein. SEDS 
reduced the particle size from 25.335 µm to 0.614 µm and the particle morphology was transformed to 
flakes in comparison to original rod shaped crystals. The in vitro release studies demonstrated 50 % of the 
drug release in approximately 20 min, and over 80 % of the baicalein was released in 60 min. However, the 
original powder exhibited a much slower dissolution rate, and less than 25 % of the baicalein was released 
in 60 min. The faster dissolution rate of baicalein microparticles was attributed to the reduced particle size 
of the baicalein and the extremely large specific surface area [46]. Likewise, the micronization of 
resveratrol via SEDS enhanced its solubility by approximately 2.8 times and the dissolution rate by 1.8 fold. 
The antioxidant efficacy of the resultant product was also enhanced significantly [47]. SEDS has been 
investigated to enhance solubility of bixin [48] and the dissolution rate of aescin by 5.5. fold [49]. 
 
Figure 3. Operational design of SEDS for the formation of micronized particles 
The process can also be utilized for development of solid dispersion of poorly water soluble drugs. 
Water-soluble PVP and astaxanthin nanocoprecipitates were successfully prepared by SEDS precipitation. It 
was found that the operating pressure, temperature, PVP:astaxanthin ratio, and Z-isomer content of 
astaxanthin affected the particle size and the astaxanthin content in the coprecipitates. The researchers 
selectively used Z-isomers of astaxanthin as it has higher bioavailability and antioxidant capacity, than the 
E-isomer. The authors predicted that use of PVP-Z-isomers of astaxanthin coprecipitates would improve its 
functionality [50].  
Lee et al. [51] investigated the application of SEDS to improve aqueous solubility of and rographolide 
through particle engineering. The sticky crude Andrographis paniculata extract was precipitated into 
powder from CO2-acetone system and CO2-acetone:ethanol (1:1 v/v) system. The modification of aqueous 
solubility of andrographolide was then attempted by manipulating its precipitation process. A. paniculata 
powder precipitated from CO2-acetone system at 150 bar and 40 °C consisted of large, irregularly shaped, 
less crystalline particles with the highest andrographolide aqueous solubility (two fold increment 
compared to crude extract). Complete dissolution of andrographolide from A. paniculata powder 
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precipitated from CO2-acetone system was achieved within 90 min. Based on the higher aqueous solubility 
and dissolution of andrographolide, and different morphology observed from the less crystalline A. 
paniculata powder precipitated from CO2-acetone system, it was concluded that fewer impurities could 
have co-precipitated with andrographolide. Conclusively, the SEDS process offers many advantages over 
conventional SAS technique such as requirement of less solvent, applicability for thermosensitive materials 
and less concentration of residual solvent in the product. 
PGSS for particle generation 
PGSS is a favorable technique for polymeric encapsulation of drugs, proteins and peptides as fine 
particles without employing organic solvents. In this process, carriers such as polymers are melted with the 
dissolved or suspended active pharmaceutical ingredient (API) contained within them (Fig. 4). The resulting 
product is then equilibrated with supercritical-CO2 and expanded through a nozzle in an expansion 
chamber in order to form fine and porous composite particles [52]. Several carriers and APIs have been 
micronized using a PGSS process [53,54]. For example, ibuprofen has been successfully micronized with 
different carrier materials such as polyethylene glycol (PEG) 6000 [55], poloxamers, Gelucire1 and glyceryl 
monostearate [56]. PEG 4000 has also been used as a carrier for the micronization of poorly water-soluble 
drugs [57]. 
 Another particle generation process close to PGSS has been described by Sievers et al. [58] that 
consists of production of a dense fine droplet aerosol plume followed by a drying step. The aim of this 
process was to obtain fine particles usable in a dry powder inhaler form. This patented process has been 
used with lactose, for developing dry powder inhaler of anti asthamatic drugs: albuterol sulfate and 
cromolyn sodium. The product comprised of fine spherical particles in the range of 0.1– 3 µm making them 
suitable for inhalation. 
 
Figure 4. Schematic illustration of working of PGSS (Particles from Gas Saturated Solution) 
In the experiments carried out in a pre-expansion pressure range from 100-200 bar, the particle size of 
nifedipine was reduced from 50 to 15 µm. At higher pressures smaller particles were formed. With the 
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particle size reduction the dissolution rate increased to some extent, but the anticipated effective surface 
area was probably reduced by the drug's hydrophobicity and agglomeration of the particles during 
micronization [59]. Pestieau et al. [60] optimized PGSS process for a fenofibrate lipid-based solid dispersion 
formulation. The researchers aimed to develop a formulation containing fenofibrate and Gelucire1 50/13 
(Gattefossé, France) in order to improve the oral bioavailability of the drug. The PGSS process was 
optimized according to the in vitro drug dissolution profile obtained using a biphasic dissolution test. Based 
on the fact that the propensity of drug precipitation during in vitro testing of lipid-based formulations can 
serve as a potential indicator for the in vivo performance of a drug, the authors predicted less time to 
reach Cmax and its sustainment for longer period for PGSS derived solid dispersion than conventional solid 
dispersions. The authors also deduced that these formulations may avoid the precipitation of this poorly 
water- soluble drug in vivo. Furthermore, an increase in apparent solubility induced by the formulation 
used can lead to an enhancement of a drug's permeability through biological membranes. Thus, 
improvement of the oral bioavailability of fenofibrate should be more pronounced with the PGSS 
formulation as a result of supersaturation being maintained for longer period.  
Fenofibrate solid dispersions were also investigated by Krananja et al. [61]. The authors used PGSS 
process for the carrier materials: Brij 5100 and polyethylene glycol PEG 4000, for the incorporation of the 
insoluble drugs nimodipine, fenofibrate, and o-vanillin with the purpose of improving their bioavailability 
and dissolution rate. The authors however, reported primarily the influence of processing parameters of 
PGSS on process yield, particle size distribution, loading efficiency and dissolution rates. The general 
conclusion was that with increasing pre-expansion pressure, the mean particle size of nimodipine-Brij S100, 
vanillin-Brij S100, and vanillin-PEG 4000 solid dispersion(s) decreased. In the case of a mixture of 
fenofibrate-Brij S100, the anticipated effective surface area was slightly reduced with pressure as a result 
of agglomeration. The loading efficiency of drugs in carriers was high and the particles obtained were 
irregular in shape. The authors deduced that a combination of factors, including particle size reduction and 
interaction between drug(s) and hydrophilic carrier(s), contributed to enhancing the dissolution rates of 
precipitated solid particles. On average, a 3.5-fold greater amount of nimodipine was dissolved in 1 h from 
solid dispersions, compared to unprocessed nimodipine. Dissolution profiles were compared with a 
different f1 factor and a similarity factor f2. It was confirmed that the dissolution character of processed o-
vanillin and fenofibrate by PGSS was different from that of unprocessed o-vanillin and fenofibrate. 
The PGSS process is not limited to production of solid dispersions; the technique also finds applications 
in production of a variety of composite particles namely solid lipid particles, microparticles and 
microcapsules that have potential to modulate drug release and thereby bioavailability. Table 5 presents a 
cross section of such research reports. 
PGSS process is simpler in operation than other techniques as the therapeutic substance need not be 
necessarily solubilized in the supercritical fluid (CO2). It requires low solvent gas supplies and pressure for 
operative purposes as compared to other processes. PGSS process can be employed to develop inorganic 
powders into multifunctional pharmaceutical compounds. However, precautions need to be taken while 
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Table 4. A cross section of composite particles of drugs prepared using PGSS process 
API and excipients 





Curcumin embedded solid 
lipid particles were 
developed via PGSS with less 
quantity of organic solvent. 
The use of helium in the process of PGSS, for designing of 
lipid mixture exhibited improvement in the 







PGSS was employed for the 
enhancement of solubility of 
(+)-ibuprofen using 
hydrophilic or hydrophobic 
carrier. 
Spherical and porous particles (50-200 µm) with 90 % 
encapsulation efficiency were produced. The solubility of 
ibuprofen was significantly enhanced with poloxamer in 
the gastro-intestinal fluids; gelucire and GMS did not 






Geleol™ and Gelucire 
50/13™ 
For production of structured 
lipid carriers a liquid 
glycerolipid (GMO), was 
incorporated into three solid 
glycerolipids with 
hydrophilic-lipophilic balance 
ranging from 1 to 13 and 
compared with solid lipid 
particles. 
 
Irregular porous microparticles with a wide particle size 
distribution were obtained. The drug loading capacity of 
the structured lipid carriers increased as the GMO content 
in the particles increased, achieving a maximum 
encapsulation efficiency of 97 % for the 3:1 mass ratio. The 
structured lipid carriers presented an immediate release of 
ketoprofen from its matrix with higher permeation through 
a mucous-membrane model, while solid lipid particles 




lecithin, and pluronic 
L64 
To modify bioavailability of 
quercetin through 
microencapsulation  
More homogenous lyophilized less crystalline encapsulated 





β- carotene was 
encapsulated in poly- 
caprolactones, and 
precipitated out using PGSS 
process. 
Small, regular, uniform, microencapsulated β-carotene 
particles in the size range of 100 –600 μm were obtained, 




Microparticles of chalcone 
alone and with lipid carriers 
were developed via PGSS and 
the solubility was analyzed. 
The lipid carriers influenced the solubility of trans-chalcone 




salmon oil and 
astaxanthin 
Microparticles of omega-3 
PUFA-rich salmon oil in PEG-
6000 were developed 
through PGSS concept. 
Developed microparticles showed significant 
thermogravimetric stability up to 350 °C. Moreover, in vitro 
release of oil in fluids stimulating gastric conditions was 
faster than in distilled water. 
[68] 
 
Other supercritical fluid techniques for enhancement of solubility 
Rapid expansion of a supercritical solution into a liquid solvent (RESOLV) 
When the traditional RESS is modified by expanding the supercritical solution into a liquid solvent 
instead of ambient air it is termed as rapid expansion of a supercritical solution into a liquid solvent 
(RESOLV). This technique can be used for the production of nanoscale particles (less than 50 nm in average 
diameter) from a CO2 soluble polymer [69]. The development of versatile methods for the preparation of 
homogeneously distributed nanoscale drug particles and their stable aqueous suspension is still a major 
challenge, despite the extensive effort based on traditional techniques.  
RESOLV was employed for the production of drug nanoparticles of two model drugs: ibuprofen and 
naproxen, which are somewhat soluble in supercritical CO2 and practically insoluble in water. The RESOLV 
process yielded aqueous suspensions of homogeneously distributed ibuprofen (average size of 40 nm in 
diameter and a size distribution standard deviation of 8.5 nm) and naproxen nanoparticles of average size 
of 64 nm in diameter and a size distribution standard deviation of 10 nm. The nanoparticles agglomerated 
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to form larger aggregates on a longer time scale. The agglomeration can be minimized by the presence of a 
stabilization agent, e. g. poly (N-vinyl-2-pyrrolidone) in the aqueous suspension. The technique may serve 
as a “clean” way for nanosizing the drug particles and the preparation of stable suspensions thereof for 
formulation and other delivery related requirements, specifically addressing the bioavailability issues [70]. 
Depressurization of an Expanded Liquid Organic Solution (DELOS) 
Polymorphism is very common in pharmaceutical drug substances since their solubility and 
bioavailability are determined by the crystalline structure adopted by the solid drugs [71]. In addition, the 
drug substance will in most cases be handled as a solid in some stages of the manufacturing process, and 
its handling and stability properties may depend on the solid phase. Consequently, the control of the 
production of a given solid polymorph is of the utmost importance in such commercial applications and 
industries. In a study by Sala et al. [72] it was observed that the precipitation of pure monoclinic E form of 
stearic acid was favored by DELOS process, a kinetically controlled crystallization in which high 
supersaturation levels are rapidly achieved. Remarkably, the DELOS process for the first time provided a 
pure polymorphic monoclinic E form, without the presence of traces from other polymorphs that always 
are present when using other kinetically driven methods, such as the conventional fast cooling. On the 
contrary, the C polymorph was preferentially obtained by the thermodynamically controlled GAS technique 
in which the increase of the solution supersaturation is slow or low supersaturation levels are attained.  
DELOS can be used as a route to obtain nutraceutical products that might show enhanced functional 
properties. Phytosterols are absorbed to a much smaller extent in the body compared to cholesterol and 
they interfere with the intestinal absorption of cholesterol. DELOS methodology has the potential to 
process phytosterols into micrometer or submicrometer particles, which is not possible with conventional 
technologies. Moreno-Calvo et al. [73] processed β-sitosterol through DELOS thereby reducing the crystals 
from 188 μm to <6.5 μm, with a narrow size distribution at all processing conditions employed. The new 
phase showed higher chemical purity and higher crystallinity than the native mixture. The authors 
recommend further studies to confirm the expected enhancement of absorption and bioavailability of β-
sitosterol. 
Aerosol Solvent Extraction System (ASES) 
ASES methodology has been used extensively for processing pharmaceuticals and biopolymers and is 
capable of producing micrometer sized or nanosized particles with low levels of residual solvent [74]. 
Furthermore, in the ASES process the particle size and morphology can be easily modulated by the 
optimization of the processing parameters. The therapeutic applications of silybin, an antihepatotoxic 
polyphenolic substance, are strongly limited by its poor solubility and low bioavailability. The issues can be 
addressed by designing nanodrug via ASES. In the process, water soluble and biocompatible PVP was used 
to improve the dissolution rate and bioavailability of silybin. The size of the silybin PVP nanodrug was to 
the tune of 100 to 300 nm. Compared with raw silybin, the nanodrug had low crystallinity and hence 
showed solubility enhancement by more than 8-fold and hence in dissolution too [74].  
Copper-indomethacin is a non-steroidal anti-inflammatory drug currently available for veterinary use. 
Its application is limited to oral formulations because of its poor solubility in biocompatible solvents. 
Meure et al. [75] prepared microspheres of PVP and copper-indomethacin that ranged in size from 50 nm 
to 4 μm. A coprecipitate containing 10 %wt copper-indomethacin and 90 %wt PVP was found to be at least 
93 times more soluble in ethanol than factory-grade copper-indomethacin. The significance of these results 
is that the coprecipitate of copper-indomethacin may be used for parenteral applications [75]. 
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Rao et al. [76] suggested enhancement of the dissolution rate, apparent solubility and oral bio-
availability of tadalafil by nanosized amorphous particles prepared by using antisolvent precipitation. 
Optimization of processing parameters yielded amorphous tadalafil solid dispersion of approximately 5-
10 μm. The solid dispersion obtained using the optimized process conditions exhibited 8.5 times faster 
dissolution rates in the first minute of dissolution, 22 times greater apparent solubility at 10 min and a 
3.67-fold increase in oral bioavailability than the unprocessed tadalafil.  
Supercritical solvent impregnation (SSI) 
Among the different approaches that employ supercritical fluids for pharmaceutical purposes, polymer 
impregnation techniques have been recently used in literature to achieve the impregnation of many kinds 
of polymers namely, poly(lactic-co-glycolic acid), ethyl/methyl cellulose, poly(dimethylsiloxane), 
poly(methyl methacrylate, etc. with a drug [77]. In particular, reports where PVP was impregnated with 
some crystalline drugs (i.e. carbamazepine, ibuprofen, ketoprofen) can be found [78-80]. In these 
processes, the crystalline drug is dissolved by supercritical CO2 and thus conveyed through the swollen 
polymeric matrix until the partition equilibrium takes place between the phases. The encapsulated 
particles display extensive solubility, better diffusion and substantial dissolution profile owing to the 
supercritical fluid that plays a role of cosolvent.  
In a study by Banchero et al. [81] successful impregnation was reported for all the PVP K15-piroxicam 
systems at 300 bar and 100 °C. Good results in terms of acceleration in the drug release were obtained 
with the PVP K15-piroxicam system. The best result was obtained for the impregnated sample containing a 
piroxicam amount equal to 11.3 %, which released 94.7 % of the drug after 10 min, with respect to 7.8 % 
released by the corresponding physical mixture after the same period of time. 
Gas Antisolvent process (GAS) 
In the GAS processes, a solute is dissolved in solvent and loaded into a crystallizer. The solution is then 
expanded by injecting carbon dioxide into the crystallizer. A sharp reduction of solute solubility in liquid 
phase is observed and subsequently particle precipitation occurs. This technique is used for drugs with low 
solubility in the supercritical fluid. The mean particle size and particle size distribution are controlled by 
GAS variables. Various drugs have been micronized by GAS process namely, microparticle production of 
carbamazepine [82], controlled crystallization of β-carotene [83], caffeine [84], phenanthrene [85] and 
paracetamol [86]. Control of GAS processing variables resulted in a decrease in ampicillin particle size from 
359 to 260 nm. The mean particle size was 425 nm for the lowest pressure (9 MPa). When the pressure 
was increased, a smaller mean particle size (220 nm) was obtained. The smaller mean particle size was 
observed at the lower temperature and low solute concentration [87]. 
All the detailed SCF techniques are virtuous alternatives for micronization and nanonization of drugs 
that require particle engineering for modification and improvement of solubility. SCF processes are 
frequently utilized to formulate readily solubilized drug carrier systems i.e. microparticles, nanoparticles, 
inclusion complexes, solid dispersions, macromolecular powders and microporous foams. Some of these 
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Table 6. A cross-section of research reports on micronized particles using discrete SCF technology 
SCF Process  API Purpose   Highlight Ref 





Ibuprofen showed same solubility profile, both in 
CO2-expanded ethanol and CO2–expanded acetone 
mixtures; whereas the naproxen solubility was 
greatly dependent on the nature of the solvent i.e. 
high in CO2–expanded ethanol. 
[88] 
RESOLV Gambogic acid Nanoparticles of 
gambogic acid were 
prepared to improve 
solubility. 
Results outlined successfully preparation of 
nanosuspension of gambogic acid. Extended 
solubility data was correlated with density-based 
models that suggested enhanced bioavailability and 
antineoplastic efficacy of nanosized gambogic acid. 
[89] 
DELOS Phytosterol Nanonization and 
decrease crystallinity of 
phytosterol to modify 
solubility 
Phytosterol nanoparticles were formulated through 
fast cooling, The crystallinity of the impregnated 
phytosterols was found to decrease in comparison 
to the pure phytosterol that modified water 
solubility.  
[90] 




retinyl palmitate  
Nanoparticles of PLLA 
retinyl palmitate were 
developed with Pluronic 
F127, F68 and sodium 
dodecyl sulfate  
Spherical PLLA- retinyl palmitate nanoparticles were 
prepared that possessed mean size of 40–110 nm 






stabilization as ultrafine 
particles of fenofibrate 
The mean particle size was approximately 3 μm, 
which suggested improved solubility. The particles 
were found to be stable for 24 h.  
[92] 
GAS Resveratrol  and 
isoniazid, 
nicotinamide 
Co-crystals of resveratrol 
were prepared with 
isoniazid and 
nicotinamide using CO2 
antisolvent  
The developed co-crystals exhibited enhanced 
bioavailability when compared to original 
resveratrol.  
[93] 
GAS 5-fluorouracil  Halloysite clay 
nanocarrier was 
developed to obtain high 
drug loading of 5-
fluorouracil 
Prepared nanocarrier loaded with 5-fluorouracil 
released significantly high drug release at pH 7.4 
owing to improve solubility. 
[94] 
SSI Quercetin Quercetin was 
impregnated on Silica to 
enhance solubility 
Several parameters i.e. temperature, time, pressure, 
and different cosolvents in the supercritical 
impregnation process were reported influential for 
quercetin solubility. 
[95] 
SSI Promogran  Promogran was 
embedded on a 
spilanthol-enriched 
extract to modify 
solubility 
Jambu extract that is completely soluble in fluid 
phase, was used to demonstrate enhanced solubility 
of promogran. A 4 h processing period was used for 
complete dissolution of the extract in SCF.  
[96] 
ASES Irbesartan Development of 
Irbesartan micro-particles 
and its composite micro-
particles  
Results highlighted modified solubility (7.5 times) 
and dissolution rate of Irbesatan microparticles 
compared to pure drug.  
[97] 
ASES β-sitosterol Preparation of 
submicroparticles of β-
sitosterol 
Powdered submicroparticles of β-sitosterol 
exhibited improved solubility.  
[98] 
ASES Itraconazole  Preparation of solid-
inclusion complexes of 
itraconazole with HP-β-
CD 
ASES-processed ITR-HP-β-CD inclusion complex solid 
powder showed 90 % drug dissolution within 10 
minutes. 
[99] 
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Conclusions 
Supercritical fluid techniques for micronization and solubility enhancement have been progressively 
applied in pharmaceutical industry. The characteristic advantages of SCF technology include non-toxicity, 
eco-friendly and flexibility that make it suitable for green chemistry. SCF processes are proven promising 
strategies to develop and design drug delivery system of those drugs whose solubility and bioavailability is 
significantly low. Moreover, SCF technologies are also utilized for formulating drug carrier owing to unique 
solvent features that can be readily modified by altering operating temperature and pressure. Several 
issues still remain i.e. the influence of operating parameters on the characteristics of the particle produced 
(size, morphology, polymorphism), the comprehension of the fluid dynamics, the nucleation phenomenon, 
the crystal growth under provided conditions etc. Whatsoever, the technology has arrived and is promising 
green option for pharmaceutical development. 
Conflict of interest: The author declares no conflict of interest. 
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